Understand Business Like AI

Training Example: Alexion, AstraZeneca Rare Disease – Review the Data, Give Your Score & Compare to the Real AI Evaluation

Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims: advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags: FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns: homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations: specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…

Alexion, AstraZeneca Rare Disease

(https://alexion.com) 📸 Data Snapshot: May 26, 2026

Analyze the raw signals below. How would a machine score this business’s credibility?

Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.

🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Alexion Global Site (https://alexion.com)
Title

Alexion Global Site

Meta

As Alexion, AstraZeneca Rare Disease, we are delivering life-changing therapies to people living with rare diseases.

H1 Pioneering new possibilities for the rare disease community
H2 About Alexion
H2 Our Science
H2 Research and Development
H2 Innovation
H2 Therapy Areas
H2 Our Impact in Rare
H2 Supporting Patients and Caregivers
H2 Partnering
H2 Media
H2 Pushing the Boundaries of Science
H2 Featured Stories
H2 Leaving Our Site
H3 Paving Regulatory Pathways in Rare Disease
H3 Advancing Rare Disease Research Through Patient-Centric Trial Design
H3 Addressing the Unmet Needs of the Amyloidosis Community
H3 Getting to know Nick France, an Alexion R&D Leading Voice
H3 Getting to know Chathuri Daluwatte, an Alexion R&D Leading Voice
H3 Getting to know Seng Cheng, an Alexion R&D Leading Voice
H3 Getting to know Sophia Zilber, Associate Director, Statistical Programming
H3 Getting to know Banu Sankaran, an Alexion R&D Leading Voice
H3 Driving health equity for the rare disease community
H3 Understanding & Overcoming the Challenges in Rare Disease Clinical Trials
H3 About Alexion
H3 Rare Disease Community
H3 Medical Community
H3 Connect
NAV_HEADER_HEADING_REPEATED News Centre Resources | Alexion Global Site (https://alexion.com/news-centre-resources/)
Title

News Centre Resources | Alexion Global Site

H1 News Centre Resources
H2 About Alexion
H2 Our Science
H2 Research and Development
H2 Innovation
H2 Therapy Areas
H2 Our Impact in Rare
H2 Supporting Patients and Caregivers
H2 Partnering
H2 Media
H2 Leaving Our Site
H3 About Alexion
H3 Rare Disease Community
H3 Medical Community
H3 Connect
NAV_HEADER_HEADING_REPEATED_BODY_FOOTER Living with Rare Disease | Alexion Global Site (https://alexion.com/living-in-rare/)
Title

Living with Rare Disease | Alexion Global Site

Meta

Understanding the challenges of a rare diagnosis and the journey that follows is critical to the work we do. That's why we partner so closely with patients and caregivers to ensure it's their stories and experiences that inform our research and development.

H1 Living with Rare Disease
H2 About Alexion
H2 Our Science
H2 Research and Development
H2 Innovation
H2 Therapy Areas
H2 Our Impact in Rare
H2 Supporting Patients and Caregivers
H2 Partnering
H2 Media
H2 Patient-Focused Innovators
H2 Co-creating Community Solutions
H2 Did you know?
H2 Rare Disease by the Numbers
H2 Striving for Equity in Rare
H2 Leaving Our Site
H3 References
H3 About Alexion
H3 Rare Disease Community
H3 Medical Community
H3 Connect
NAV_HEADER_HEADING_REPEATED_BODY_FOOTER Innovation | Alexion Global Site (https://alexion.com/innovation/)
Title

Innovation | Alexion Global Site

H1 Innovation
H2 About Alexion
H2 Our Science
H2 Research and Development
H2 Innovation
H2 Therapy Areas
H2 Our Impact in Rare
H2 Supporting Patients and Caregivers
H2 Partnering
H2 Media
H2 Leaving Our Site
H3 Data Science and AI
H3 Diagnostics
H3 Genomics
H3 About Alexion
H3 Rare Disease Community
H3 Medical Community
H3 Connect
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://alexion.com) Alexion Global Site 
[IMG: Rare Disease Day Article]

[H1]
Pioneering new possibilities for the rare disease community

Read More

[H1]
More than 400 Million People Live with a Rare Disease

Living with Rare

[H1]
Leading the Charge in Rare Disease Research

Rare Disease Research & Development

Our Mission

We are pioneering new possibilities for the rare disease community.

Our Innovation

[H2] Pushing the Boundaries of Science

Our research and development is fueled by a relentless sense of urgency and an steadfast commitment to helping more rare disease patients and their families around the world.Learn how we are addressing some of today’s most pressing rare disease challenges by investigating in new targets, modalities and technologies, with more opportunities for innovation than ever before.

Our Innovation in Rare

[H2] Featured Stories

[IMG: Holding Hands]

Health Equity
•
May 21, 2026

Understanding treatment impact and addressing disparities in rare disease care

[IMG: Tinas Big Trip]

Article
•
May 11, 2026

Tina’s Big Trip

[IMG: Rare Disease Day]

Article
•
February 03, 2026

Pioneering new possibilities for the rare disease community

[IMG: View globe from space]

Clinical Trials
•
October 28, 2025

Shaping the future of R&D with real world insights into rare disease

[IMG: Newborn Screening]

Diagnostics
•
September 17, 2025

Genomic Innovation to Support Newborn Screening of Rare Diseases

[IMG: Sarah Rhee]

Thought Leadership
•
June 11, 2025

[H3] Paving Regulatory Pathways in Rare Disease

Many rare disease medicines are often a first of their kind, and a clear roadmap for their development and approval does not exist. Navigating the complex and sometimes unprecedented regulatory environment for rare disease requires innovation, collaboration and a patient-first mindset.

Media [News]
•
April 10, 2025

[H3] Advancing Rare Disease Research Through Patient-Centric Trial Design

As Head of Development, Regulatory and Safety at Alexion, Gianluca Pirozzi channels his life’s experience with rare disease to inform his work at Alexion, ensuring clinical programmes are fueled by a patient-focused mindset.

Patient Support
•
February 05, 2025

[H3] Addressing the Unmet Needs of the Amyloidosis Community

We spoke with Cristina Quarta, Executive Medical Director, about a group of rare diseases known as amyloidosis, the medical needs within this community and how her work as a cardiologist shapes her approach to research and development (R&D) for rare cardiac conditions.

Research and Development
•
September 18, 2024

[H3] Getting to know Nick France, an Alexion R&D Leading Voice

To create meaningful advances in rare disease research, it takes an innovative culture, strong collaboration, and a patient-centric vision for delivering transformational solutions. At Alexion, these pillars are important to successfully develop impactful medicines for patients.

Patient Support
•
June 25, 2024

[H3] Getting to know Chathuri Daluwatte, an Alexion R&D Leading Voice

Artificial Intelligence (AI) is rapidly advancing and has the potential to have a transformative impact on clinical research and development (R&D).

Research and Development
•
June 08, 2024

[H3] Getting to know Seng Cheng, an Alexion R&D Leading Voice

There is a sense of urgency that underlies research in rare diseases, because these diseases are often rapidly progressive.

Patient Support
•
April 18, 2024

[H3] Getting to know Sophia Zilber, Associate Director, Statistical Programming

The voices and perspectives of patients play an essential role in rare disease research and development (R&D).

Patient Support
•
April 16, 2024

[H3] Getting to know Banu Sankaran, an Alexion R&D Leading Voice

Diagnostics and artificial intelligence (AI) systems are transforming research and development (R&D) in the healthcare industry.

Health Equity
•
February 06, 2024

[H3] Driving health equity for the rare disease community

Collectively, more than 400 million people around the world are living with a rare disease, defined as conditions that affect a small number of people compared to the general population.

Clinical Trials
•
November 07, 2023

[H3] Understanding & Overcoming the Challenges in Rare Disease Clinical Trials

Why is conducting clinical trials for rare diseases difficult? Because studying a rare disease poses unique challenges and requires thinking differently.

View All News

Veeva ID: GL/ALL/0071
6104 chars
SUB-PAGE · THIN (https://alexion.com/news-centre-resources/) News Centre Resources | Alexion Global Site 
Home

News Centre Resources
49 chars
SUB-PAGE (https://alexion.com/living-in-rare/) Living with Rare Disease | Alexion Global Site 
Home

Living with Rare Disease

[H2]
Patient-Focused Innovators

Cultivating deep connections to integrate their insights and lived experience into everything we do.

[H2]
Co-creating Community Solutions

Understanding the challenges of a rare diagnosis and the journey that follows is critical to the work we do. That's why we partner so closely with patients and caregivers to ensure it's their stories and experiences that inform our research and development.
Our partnerships with the rare disease community are essential to addressing the unique burdens facing the rare disease community.  Together we co-create solutions and amplify awareness, while shaping policies and ecosystems needed to advance access to innovation.

[H2] Did you know?

With more than 400 million people worldwide living with a rare disease, and 10,000 rare diseases known to exist today, rare diseases are not as rare as we may think.1

[H2]
Rare Disease by the Numbers

References.1-5

10,000+

rare diseases that we know of

~ 5 Years

on average, and often more, to get an accurate rare disease diagnosis

1 in 2

patients diagnosed with a rare disease is a child

80%

of rare diseases are genetic

90%

of rare diseases do not have an approved treatment

[H2] Striving for Equity in Rare

People living with rare diseases can face significant challenges like lack of treatment options and access to care. These challenges weigh even more heavily on racial and ethnic minorities and marginalized groups, leading to economic hardship, difficulty accessing care, and poorer outcomes for both patients and caregivers.6-8

Explore Health Equity in Rare

[H3]
References

Rare disease facts [Internet]. 2024 [cited 2024 Jan 17]. Available from: https://globalgenes.org/rare-disease-facts
Fermaglich LJ, et al. A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act. Orphanet J Rare Dis. 2023;18(1):163.
U.S. Department of Health & Human Services. About GARD. Available here. Accessed December 2024.
National Organization for Rare Disorders. Barriers to rare disease diagnosis, care and treatment in the US: a 30-year comparative analysis. Available here. Accessed December 2024.
National Human Genome Research Institute. Rare genetic diseases. Available here. Accessed December 2024.
EveryLife Foundation for Rare Diseases. Challenges to diversity in rare diseases. Available here. Accessed December 2024.
Rare Disease Diversity Coalition. Inequities in the rare disease community. Available here. Accessed December 2024.
Office of the Assistant Secretary for Planning and Evaluation. Participant diversity by race, ethnicity, and sex in rare disease clinical trials: a case study of eight rare cancers. Available here. Accessed December 2024.

Veeva ID: GL/ALL/0039
3400 chars
SUB-PAGE · THIN (https://alexion.com/innovation/) Innovation | Alexion Global Site 
Home

Innovation

[H3] Data Science and AI

Learn how AI has the potential to accelerate the pace of discovery and development.

[H3] Diagnostics

Explore ways we are helping to shorten the diagnostic journey for people living with rare disease.

[H3] Genomics

Leveraging knowledge of the genome to potentially address rare diseases with a genetic cause.

Veeva ID: GL/ALL/0057
722 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
0Review mentions (all pages)
4External proof links (all pages)
PageReviewsProof links
/ (home) 0 1
/news-centre-resources/ 0 1
/living-in-rare/ 0 1
/innovation/ 0 1
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage schema 
[
    {
        "@context": "https://schema.org",
        "@type": "Organization",
        "name": "Alexion",
        "alternateName": "Alexion",
        "url": "http://alexion.com/",
        "logo": "",
        "sameAs": [
            "https://www.instagram.com/alexionpharmaus/",
            "https://www.youtube.com/channel/UCbDpNIQcl0lsU3pmCOSJTrA",
            "https://www.linkedin.com/company/alexion-pharmaceuticals/"
        ]
    },
    {
        "@context": "https://schema.org",
        "@type": "WebSite",
        "name": "Alexion",
        "url": "http://alexion.com/"
    },
    {
        "@context": "https://schema.org",
        "@type": "BreadcrumbList",
        "itemListElement": [
            {
                "@type": "ListItem",
                "position": 1,
                "name": "Home",
                "item": "http://alexion.com/"
            }
        ]
    },
    {
        "@context": "https://schema.org",
        "@type": "ItemList",
        "itemListElement": [
            {
                "@type": "ListItem",
                "position": 1,
                "name": "Pioneering new possibilities for the rare disease community",
                "url": "http://alexion.com/sitecore/content/alexion_global/shared-content/homepage-carousel-slides/homepage-carousel-masthead-slides-pioneering-new-possibilities"
            },
            {
                "@type": "ListItem",
                "position": 2,
                "name": "More than 400 Million People Live with a Rare Disease",
                "url": "http://alexion.com/sitecore/content/alexion_global/shared-content/homepage-carousel-slides/homepage-carousel-masthead-slides-more-than-400-million-people"
            },
            {
                "@type": "ListItem",
                "position": 3,
                "name": "Leading the Charge in Rare Disease Research",
                "url": "http://alexion.com/sitecore/content/alexion_global/shared-content/homepage-carousel-slides/homepage-carousel-masthead-slides-leading-the-charge"
            }
        ]
    },
    {
        "@context": "https://schema.org",
        "@type": "ItemList",
        "itemListElement": [
            {
                "@type": "ListItem",
                "position": 1,
                "name": "Understanding treatment impact and addressing disparities in rare disease care",
                "url": "http://alexion.com/news-centre-resources/articles/understanding-treatment-impact-and-addressing-disparities-in-rare-disease-care"
            },
            {
                "@type": "ListItem",
                "position": 2,
                "name": "Tina’s Big Trip",
                "url": "http://alexion.com/news-centre-resources/articles/tinas-big-trip"
            },
            {
                "@type": "ListItem",
                "position": 3,
                "name": "Pioneering new possibilities for the rare disease community",
                "url": "http://alexion.com/news-centre-resources/articles/pioneering-new-possibilities-for-the-rare-disease-community"
            },
            {
                "@type": "ListItem",
                "position": 4,
                "name": "Shaping the future of R&D with real world insights into rare disease",
                "url": "http://alexion.com/news-centre-resources/articles/shaping-the-future-of-rd-with-real-world-insights-into-rare-disease"
            },
            {
                "@type": "ListItem",
                "position": 5,
                "name": "Genomic Innovation to Support Newborn Screening of Rare Diseases",
                "url": "http://alexion.com/news-centre-resources/articles/newborn-screening"
            },
            {
                "@type": "ListItem",
                "position": 6,
                "name": "Paving Regulatory Pathways in Rare Disease",
                "url": "http://alexion.com/news-centre-resources/articles/paving-regulatory-pathways-in-rare-disease"
            },
            {
                "@type": "ListItem",
                "position": 7,
                "name": "Advancing Rare Disease Research Through Patient-Centric Trial Design",
                "url": "http://alexion.com/news-centre-resources/articles/patient-centric-clinical-trial"
            },
            {
                "@type": "ListItem",
                "position": 8,
                "name": "Addressing the Unmet Needs of the Amyloidosis Community  ",
                "url": "http://alexion.com/news-centre-resources/articles/addressing-the-unmet-needs-of-the-amyloidosis-community"
            },
            {
                "@type": "ListItem",
                "position": 9,
                "name": "Getting to know Nick France, an Alexion R&D Leading Voice",
                "url": "http://alexion.com/news-centre-resources/articles/getting-to-know-nick-france"
            },
            {
                "@type": "ListItem",
                "position": 10,
                "name": "Getting to know Chathuri Daluwatte, an Alexion R&D Leading Voice",
                "url": "http://alexion.com/news-centre-resources/articles/getting-know-chathuri-daluwatte-alexion-rd-leading-voice"
            },
            {
                "@type": "ListItem",
                "position": 11,
                "name": "Getting to know Seng Cheng, an Alexion R&D Leading Voice",
                "url": "http://alexion.com/news-centre-resources/articles/getting-know-seng-cheng-alexion-rd-leading-voice"
            },
            {
                "@type": "ListItem",
                "position": 12,
                "name": "Getting to know Sophia Zilber, Associate Director, Statistical Programming",
                "url": "http://alexion.com/news-centre-resources/articles/getting-know-sophia-zilber-associate-director-statistical"
            },
            {
                "@type": "ListItem",
                "position": 13,
                "name": "Getting to know Banu Sankaran, an Alexion R&D Leading Voice",
                "url": "http://alexion.com/news-centre-resources/articles/getting-know-banu-sankaran-alexion-rd-leading-voice"
            },
            {
                "@type": "ListItem",
                "position": 14,
                "name": "Driving health equity for the rare disease community",
                "url": "http://alexion.com/news-centre-resources/articles/driving-health-equity-rare-disease-community"
            },
            {
                "@type": "ListItem",
                "position": 15,
                "name": "Understanding & Overcoming the Challenges in Rare Disease Clinical Trials",
                "url": "http://alexion.com/news-centre-resources/articles/understanding-overcoming-challenges-rare-disease-clinical-trials"
            }
        ]
    }
]
/news-centre-resources/ 
[
    {
        "@context": "https://schema.org",
        "@type": "Organization",
        "name": "Alexion",
        "alternateName": "Alexion",
        "url": "http://alexion.com/news-centre-resources",
        "logo": "",
        "sameAs": [
            "https://www.instagram.com/alexionpharmaus/",
            "https://www.youtube.com/channel/UCbDpNIQcl0lsU3pmCOSJTrA",
            "https://www.linkedin.com/company/alexion-pharmaceuticals/"
        ]
    },
    {
        "@context": "https://schema.org",
        "@type": "WebSite",
        "name": "Alexion",
        "url": "http://alexion.com/news-centre-resources"
    },
    {
        "@context": "https://schema.org",
        "@type": "BreadcrumbList",
        "itemListElement": [
            {
                "@type": "ListItem",
                "position": 1,
                "name": "Home",
                "item": "http://alexion.com/"
            },
            {
                "@type": "ListItem",
                "position": 2,
                "name": "News Centre Resources",
                "item": "http://alexion.com/news-centre-resources"
            }
        ]
    }
]
/living-in-rare/ 
[
    {
        "@context": "https://schema.org",
        "@type": "Organization",
        "name": "Alexion",
        "alternateName": "Alexion",
        "url": "http://alexion.com/living-in-rare",
        "logo": "",
        "sameAs": [
            "https://www.instagram.com/alexionpharmaus/",
            "https://www.youtube.com/channel/UCbDpNIQcl0lsU3pmCOSJTrA",
            "https://www.linkedin.com/company/alexion-pharmaceuticals/"
        ]
    },
    {
        "@context": "https://schema.org",
        "@type": "WebSite",
        "name": "Alexion",
        "url": "http://alexion.com/living-in-rare"
    },
    {
        "@context": "https://schema.org",
        "@type": "BreadcrumbList",
        "itemListElement": [
            {
                "@type": "ListItem",
                "position": 1,
                "name": "Home",
                "item": "http://alexion.com/"
            },
            {
                "@type": "ListItem",
                "position": 2,
                "name": "Living with Rare Disease",
                "item": "http://alexion.com/living-in-rare"
            }
        ]
    }
]
/innovation/ 
[
    {
        "@context": "https://schema.org",
        "@type": "Organization",
        "name": "Alexion",
        "alternateName": "Alexion",
        "url": "http://alexion.com/innovation",
        "logo": "",
        "sameAs": [
            "https://www.instagram.com/alexionpharmaus/",
            "https://www.youtube.com/channel/UCbDpNIQcl0lsU3pmCOSJTrA",
            "https://www.linkedin.com/company/alexion-pharmaceuticals/"
        ]
    },
    {
        "@context": "https://schema.org",
        "@type": "WebSite",
        "name": "Alexion",
        "url": "http://alexion.com/innovation"
    },
    {
        "@context": "https://schema.org",
        "@type": "BreadcrumbList",
        "itemListElement": [
            {
                "@type": "ListItem",
                "position": 1,
                "name": "Home",
                "item": "http://alexion.com/"
            },
            {
                "@type": "ListItem",
                "position": 2,
                "name": "Innovation",
                "item": "http://alexion.com/innovation"
            }
        ]
    },
    {
        "@context": "https://schema.org",
        "@type": "ItemList",
        "itemListElement": [
            {
                "@type": "ListItem",
                "position": 1,
                "name": "Data Science and AI",
                "url": "http://alexion.com/innovation/data-science-and-ai"
            },
            {
                "@type": "ListItem",
                "position": 2,
                "name": "Diagnostics",
                "url": "http://alexion.com/innovation/diagnostics"
            },
            {
                "@type": "ListItem",
                "position": 3,
                "name": "Genomics",
                "url": "http://alexion.com/innovation/genomics"
            }
        ]
    }
]

Your Diagnosis

Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.

Information Density 0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence 0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof 0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint 0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority 0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score 0 / 100
💡 Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)

These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.

Information Density

Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.

Semantic Alignment

Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.

Trust & Proof

Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.

Commodity Fingerprint

Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.

Identity & Authority

Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.

Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.

B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS

Based on 784 businesses audited.

BS Detector

Medical Devices, Pharma & Biotech BS: Alexion, AstraZeneca Rare Disease (alexion.com)

https://alexion.com 📍 Industry: Medical Devices, Pharma & Biotech
28 BS / 100

Alexion manages to avoid high BS scores primarily through the ‘boring substance’ of regulatory compliance and clear citations. While the top-level copy is thick with pharma-fluff, the secondary layers provide the names, dates, and references required for industry credibility.

Info Density Power-words vs. Substance ratio.
11
37% BS
Semantic Coherence Homepage promise vs. Sub-page reality.
4
20% BS
Trust & Proof Verifiable evidence vs. Trust Theatre.
2
10% BS
Commodity Fingerprint Detection of industry clichés/templates.
9
60% BS
Identity & Authority Expert verifiability & Schema depth.
2
13% BS

Populate the ‘Innovation’ sub-page with specific Phase I-III pipeline data to replace the current generic AI and Genomics blocks. Integrate Person schema for all named ‘Leading Voices’ to provide a verifiable digital footprint for their expertise. Replace the H1 power-word ‘Pioneering’ with a more specific verb that references a recent regulatory milestone or therapeutic area expansion. Add direct links to ClinicalTrials.gov for the ‘Patient-Centric Trial Design’ section to bridge the proof gap.

The content perfectly aligns with the Pharma & Biotech category, specifically focusing on the rare disease therapeutic area. Evidence includes the use of Veeva IDs (GL/ALL/0071), mentions of regulatory pathways, and clinical trial design terminology.

“The score of 28 reflects a 'Low BS' profile. Points were primarily deducted for Industry Cliché Density (Step 4) and the thin Information Density on the Innovation sub-page (Step 1). The site's adherence to pharma regulatory standards (Veeva IDs) and strong external proof paths on the living-in-rare page prevented a higher score.”

Verified Analysis Date: May 26, 2026 © 1EuroSEO Independent Evaluator — Non-Sponsored Result
Analysis Disclosure & Source Attribution

This training module utilizes a snapshot of public data from Alexion, AstraZeneca Rare Disease, captured on May 26, 2026, to demonstrate how machine logic evaluates different types of business narratives.

Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.

Notice to Alexion, AstraZeneca Rare Disease: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.

Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.

To all users: You are encouraged to visit the live site at https://alexion.com to view the most current version of its content and learn from the source what this company is about and what it offers.

Brand AI Reputation